HCPCS Code Applications and Approvals: April 2024
Quarterly archive · CMS Level II HCPCS57 coding decisions took effect April 1, 2024
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Fourth Quarter 2023 coding cycle, which took effect April 1, 2024.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
April 2024
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| C9159 | BALFAXAR Injection, prothrombin complex concentrate (human), balfaxar, per i.u. of factor ix activity | Octapharma Intravenous | Replaced byJ7165 | Discontinue | |
| C9160 | DAXXIFY Injection, daxibotulinumtoxina-lanm, 1 unit | Revance Therapeutics | Replaced byJ0589 | Discontinue | |
| C9161 | EYLEA HD Injection, aflibercept hd, 1 mg | Regeneron Pharmaceuticals Inc. Intravitreal | Replaced byJ0177 | Discontinue | |
| C9162 | IZERVAY Injection, avacincaptad pegol, 0.1 mg | Iveric Bio Intravitreal | Replaced byJ2782 | Discontinue | |
| C9163 | TALVEY Injection, talquetamab-tgvs, 0.25 mg | Johnson & Johnson Health Care Systems Inc. Subcutaneous | Replaced byJ3055 | Discontinue | |
| C9164 | YCANTH Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg) | Verrica Pharmaceuticals Inc. Topical | Replaced byJ7354 | Discontinue | |
| C9165 | ELFREXIO Injection, elranatamab-bcmm, 1 mg | Pfizer, Inc. Subcutaneous | Replaced byJ1323 | Discontinue | |
| J0177 | EYLEA HD Injection, aflibercept hd, 1 mg | Regeneron Pharmaceuticals Inc. Intravitreal | ReplacesC9161 | Establish | |
| J0208 | Sodium Thiosulfate (Pedmark) 505(b)(2) Injection, sodium thiosulfate (pedmark), 100 mg | — | — | Revise | |
| J0209 | Sodium Thiosulfate (Hope) Injection, sodium thiosulfate (hope), 100 mg | — | — | Establish | |
| J0576 | BRIXADI 505(b)(2) Injection, buprenorphine extended-release (brixadi), 1 mg | Braeburn Inc. | Replaced byJ0577 | Discontinue | |
| J0577 | BRIXADI 505(b)(2) Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy | Braeburn Inc. | ReplacesJ0576 | Establish | |
| J0578 | BRIXADI 505(b)(2) Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy | Braeburn Inc. | — | Establish | |
| J0589 | DAXXIFY Injection, daxibotulinumtoxina-lanm, 1 unit | Revance Therapeutics | ReplacesC9160 | Establish | |
| J0612 | Calcium Gluconate Injection, calcium gluconate, not otherwise specified, 10 mg | — | — | Revise | |
| J0613 | Calcium Gluconate (Wg Critical Care) Injection, calcium gluconate (wg critical care) not therapeutically equivalent to J0612, 10 mg | — | — | Revise | |
| J0650 | Levothyroxine Sodium 505(b)(2) Injection, levothyroxine sodium, not otherwise specified, 10 mcg | — | — | Establish | |
| J0651 | Levothyroxine Sodium (Fresenius Kabi) 505(b)(2) Injection, levothyroxine sodium (fresenius kabi) not therapeutically equivalent to J0650, 10 mcg | — | — | Establish | |
| J0652 | Levothyroxine Sodium (Hikma) 505(b)(2) Injection, levothyroxine sodium (hikma) not therapeutically equivalent to J0650, 10 mcg | — | — | Establish | |
| J1010 | Methylprednisolone Acetate 505(b)(2) Injection, methylprednisolone acetate, 1 mg | — | ReplacesJ1020ReplacesJ1030ReplacesJ1040 | Establish | |
| J1020 | Methylprednisolone Acetate Injection, methylprednisolone acetate, 20 mg | — | Replaced byJ1010 | Discontinue | |
| J1030 | Methylprednisolone Acetate Injection, methylprednisolone acetate, 40 mg | — | Replaced byJ1010 | Discontinue | |
| J1040 | Methylprednisolone Acetate Injection, methylprednisolone acetate, 80 mg | — | Replaced byJ1010 | Discontinue | |
| J1202 | OPFOLDA 505(b)(2) Miglustat, oral, 65 mg | Amicus Therapeutics Oral | — | Establish | |
| J1203 | POMBILITI Injection, cipaglucosidase alfa-atga, 5 mg | Amicus Therapeutics Intravenous/Oral | — | Establish | |
| J1323 | ELFREXIO Injection, elranatamab-bcmm, 1 mg | Pfizer, Inc. Subcutaneous | ReplacesC9165 | Establish | |
| J1434 | FOCINVEZ 505(b)(2) Injection, fosaprepitant (focinvez), 1 mg | Amneal Pharmaceuticals, Inc. Intravenous | — | Establish | |
| J1840 | Kanamycin Sulfate Injection, kanamycin sulfate, up to 500 mg | — | — | Discontinue | |
| J1850 | Kanamycin Sulfate Injection, kanamycin sulfate, up to 75 mg | — | — | Discontinue | |
| J2277 | APHEXDA Injection, motixafortide, 0.25 mg | BioLineRx, Ltd. Subcutaneous | — | Establish | |
| J2782 | IZERVAY Injection, avacincaptad pegol, 0.1 mg | Iveric Bio Intravitreal | ReplacesC9162 | Establish | |
| J2801 | RYKINDO 505(b)(2) Injection, risperidone (rykindo), 0.5 mg | Luye Pharma USA, Ltd Intramuscular | — | Establish | |
| J2919 | Methylprednisolone Sodium Succinate 505(b)(2) Injection, methylprednisolone sodium succinate, 5 mg | — | ReplacesJ2920ReplacesJ2930 | Establish | |
| J2920 | Methylprednisolone Sodium Succinate Injection, methylprednisolone sodium succinate, up to 40 mg | — | Replaced byJ2919 | Discontinue | |
| J2930 | Methylprednisolone Sodium Succinate Injection, methylprednisolone sodium succinate, up to 125 mg | — | Replaced byJ2919 | Discontinue | |
| J3055 | TALVEY Injection, talquetamab-tgvs, 0.25 mg | Johnson & Johnson Health Care Systems Inc. Subcutaneous | ReplacesC9163 | Establish | |
| J3380 | ENTYVIO Injection, vedolizumab, intravenous, 1 mg | Takeda Pharmaceuticals America, Inc. Intravenous/Subcutaneous | — | Revise | |
| J3424 | Hydroxocobalamin 505(b)(2) Injection, hydroxocobalamin, intravenous, 25 mg | — | — | Establish | |
| J7165 | BALFAXAR Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity | Octapharma Intravenous | ReplacesC9159 | Establish | |
| J7354 | YCANTH Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg) | Verrica Pharmaceuticals Inc. Topical | ReplacesC9164 | Establish | |
| J9070 | Cyclophosphamide Cyclophosphamide, 100 mg | — | — | Discontinue | |
| J9073 | Cyclophosphamide (Ingenus) Injection, cyclophosphamide (ingenus), 5 mg | — | — | Establish | |
| J9074 | Cyclophosphamide Injection 505(b)(2) Injection, cyclophosphamide (sandoz), 5 mg | Sandoz Inc. Intravenous | — | Establish | |
| J9075 | Cyclophosphamide 505(b)(2) Injection, cyclophosphamide, not otherwise specified, 5mg | — | — | Establish | |
| J9248 | HEPZATO 505(b)(2) Injection, melphalan (hepzato), 1 mg | Delcath Systems Inc. Intravenous | — | Establish | |
| J9249 | Melphalan Hydrochloride Injection 505(b)(2) Injection, melphalan (apotex), 1 mg | Apotex Intravenous | — | Establish | |
| J9250 | Methotrexate Sodium Methotrexate sodium, 5 mg | — | — | Discontinue | |
| J9376 | VEOPOZ Injection, pozelimab-bbfg, 1 mg | Regeneron Intravenous/Subcutaneous | — | Establish | |
| Q4244 | Procenta Procenta, per 200 mg | Lucina BioSciences, LLC | Replaced byQ4310 | Discontinue | |
| Q4305 | American Amnion AC Tri-Layer American amnion ac tri-layer, per square centimeter | BioStem Technologies | — | Establish | |
| Q4306 | American Amnion AC American amnion ac, per square centimeter | BioStem Technologies | — | Establish | |
| Q4307 | American Amnion American amnion, per square centimeter | BioStem Technologies | — | Establish | |
| Q4308 | Sanopellis Sanopellis, per square centimeter | ReNu LLC | — | Establish | |
| Q4309 | VIA Matrix Via matrix, per square centimeter | VIVEX Biologics | — | Establish | |
| Q4310 | Procenta Procenta, per 100 mg | Lucina BioSciences, LLC | ReplacesQ4244 | Establish | |
| Q5133 | TOFIDENCE Biosimilar Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg | Biogen Inc. Intravenous | — | Establish | |
| Q5134 | TYRUKO Biosimilar Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg | Sandoz Inc. Intravenous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Fourth Quarter 2023 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
